메뉴 건너뛰기




Volumn 18, Issue 4, 2007, Pages 647-651

Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases

Author keywords

Autoimmune diseases; Lymphoma; R CHOP; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINUCLEAR ANTIBODY; BIOCHEMICAL MARKER; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; GOLD; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; STEROID; VINCRISTINE;

EID: 34047100811     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl467     Document Type: Article
Times cited : (20)

References (25)
  • 1
    • 30344479938 scopus 로고    scopus 로고
    • Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype
    • Smedby KE, Hjalgrim H, Askling J et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98: 51-60.
    • (2006) J Natl Cancer Inst , vol.98 , pp. 51-60
    • Smedby, K.E.1    Hjalgrim, H.2    Askling, J.3
  • 2
    • 0037165261 scopus 로고    scopus 로고
    • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    • Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
    • (2002) N Engl J Med , vol.346 , pp. 235-242
    • Coiffier, B.1    Lepage, E.2    Briere, J.3
  • 3
    • 13244288836 scopus 로고    scopus 로고
    • Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up
    • Czuczman MS, Weaver R, Alkuzweny B et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711-4716.
    • (2004) J Clin Oncol , vol.22 , pp. 4711-4716
    • Czuczman, M.S.1    Weaver, R.2    Alkuzweny, B.3
  • 4
    • 28544435078 scopus 로고    scopus 로고
    • Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    • Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
    • (2005) Blood , vol.106 , pp. 3725-3732
    • Hiddemann, W.1    Kneba, M.2    Dreyling, M.3
  • 5
    • 0035093233 scopus 로고    scopus 로고
    • Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
    • Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 205-211.
    • (2001) Rheumatology (Oxford) , vol.40 , pp. 205-211
    • Edwards, J.C.1    Cambridge, G.2
  • 7
    • 0036785351 scopus 로고    scopus 로고
    • Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
    • Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-888.
    • (2002) Ann Rheum Dis , vol.61 , pp. 883-888
    • Leandro, M.J.1    Edwards, J.C.2    Cambridge, G.3
  • 8
    • 2942537697 scopus 로고    scopus 로고
    • Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
    • Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
    • (2004) N Engl J Med , vol.350 , pp. 2572-2581
    • Edwards, J.C.1    Szczepanski, L.2    Szechinski, J.3
  • 9
    • 1842413105 scopus 로고    scopus 로고
    • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project
    • WHO
    • WHO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
    • (1997) Blood , vol.89 , pp. 3909-3918
  • 10
    • 0042449063 scopus 로고    scopus 로고
    • Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    • NCI Sponsored International Working Group
    • Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
    • (1999) J Clin Oncol , vol.17 , pp. 1244
    • Cheson, B.D.1    Horning, S.J.2    Coiffier, B.3
  • 11
    • 0642305396 scopus 로고    scopus 로고
    • Lymphoproliferation in autoimmunity and Sjogren's syndrome
    • Voulgarelis M, Moutsopoulos HM. Lymphoproliferation in autoimmunity and Sjogren's syndrome. Curr Rheumatol Rep 2003; 5: 317-323.
    • (2003) Curr Rheumatol Rep , vol.5 , pp. 317-323
    • Voulgarelis, M.1    Moutsopoulos, H.M.2
  • 12
    • 0025813213 scopus 로고
    • Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas
    • Dighiero G, Hart S, Lim A et al. Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. Blood 1991; 78: 581-585.
    • (1991) Blood , vol.78 , pp. 581-585
    • Dighiero, G.1    Hart, S.2    Lim, A.3
  • 13
    • 0035560236 scopus 로고    scopus 로고
    • Extranodal lymphoma of MALT-type: Perspective at the beginning of the 21st century
    • Raderer M, Isaacson PG. Extranodal lymphoma of MALT-type: Perspective at the beginning of the 21st century. Expert Rev Anticancer Ther 2001; 1: 53-64.
    • (2001) Expert Rev Anticancer Ther , vol.1 , pp. 53-64
    • Raderer, M.1    Isaacson, P.G.2
  • 14
    • 33746547256 scopus 로고    scopus 로고
    • Long-term remission of Sjogren's syndrome-associated aggressive B-cell non-Hodgkin's lymphomas following administration of combined B-cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
    • Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long-term remission of Sjogren's syndrome-associated aggressive B-cell non-Hodgkin's lymphomas following administration of combined B-cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis 2006; 65(8): 1033-37.
    • (2006) Ann Rheum Dis , vol.65 , Issue.8 , pp. 1033-1037
    • Voulgarelis, M.1    Giannouli, S.2    Tzioufas, A.G.3    Moutsopoulos, H.M.4
  • 15
    • 0037732689 scopus 로고    scopus 로고
    • The role of B cells in rheumatoid arthritis: Mechanisms and therapeutic targets
    • Dorner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 2003; 15: 246-252.
    • (2003) Curr Opin Rheumatol , vol.15 , pp. 246-252
    • Dorner, T.1    Burmester, G.R.2
  • 16
    • 0033033201 scopus 로고    scopus 로고
    • Do self-perpetuating B lymphocytes drive human autoimmune disease?
    • Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999; 97: 188-196.
    • (1999) Immunology , vol.97 , pp. 188-196
    • Edwards, J.C.1    Cambridge, G.2    Abrahams, V.M.3
  • 17
    • 0035888030 scopus 로고    scopus 로고
    • T cell activation in rheumatoid synovium is B cell dependent
    • Takemura S, Klimiuk PA, Braun A et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167: 4710-4718.
    • (2001) J Immunol , vol.167 , pp. 4710-4718
    • Takemura, S.1    Klimiuk, P.A.2    Braun, A.3
  • 18
    • 27744600435 scopus 로고    scopus 로고
    • Panel discussion on B cells and rituximab: Mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma
    • Panayi GS, Hainsworth JD, Looney RJ, Keystone EC. Panel discussion on B cells and rituximab: Mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma. Rheumatology (Oxford) 2005; 44 (Suppl 2): Ii18-ii20.
    • (2005) Rheumatology (Oxford) , vol.44 , Issue.SUPPL. 2
    • Panayi, G.S.1    Hainsworth, J.D.2    Looney, R.J.3    Keystone, E.C.4
  • 19
    • 29944439246 scopus 로고    scopus 로고
    • High efficacy of rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases
    • Cervetti G, Mechelli S, Riccioni R et al. High efficacy of rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clin Exp Rheumatol 2005; 23: 877-880.
    • (2005) Clin Exp Rheumatol , vol.23 , pp. 877-880
    • Cervetti, G.1    Mechelli, S.2    Riccioni, R.3
  • 20
    • 25444437442 scopus 로고    scopus 로고
    • Rituximab treatment in patients with primary Sjogren's syndrome: An open-label phase II study
    • Pijpe J, van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjogren's syndrome: An open-label phase II study. Arthritis Rheum 2005; 52: 2740-2750.
    • (2005) Arthritis Rheum , vol.52 , pp. 2740-2750
    • Pijpe, J.1    van Imhoff, G.W.2    Spijkervet, F.K.3
  • 21
    • 7844225540 scopus 로고    scopus 로고
    • Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
    • Berinstein NL, Grillo-Lopez AJ, White CA et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
    • (1998) Ann Oncol , vol.9 , pp. 995-1001
    • Berinstein, N.L.1    Grillo-Lopez, A.J.2    White, C.A.3
  • 22
    • 0035259532 scopus 로고    scopus 로고
    • Re-treatment of relapsed indolent B-cell lymphoma with rituximab
    • Igarashi T, Ohtsu T, Fujii H et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001; 73: 213-21.
    • (2001) Int J Hematol , vol.73 , pp. 213-221
    • Igarashi, T.1    Ohtsu, T.2    Fujii, H.3
  • 23
    • 27444441270 scopus 로고    scopus 로고
    • Update on rituximab
    • Eisenberg R. Update on rituximab. Ann Rheum Dis 2005; 64 (Suppl 4): iv55-iv57.
    • (2005) Ann Rheum Dis , vol.64 , Issue.SUPPL. 4
    • Eisenberg, R.1
  • 24
    • 0032533235 scopus 로고    scopus 로고
    • Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation
    • Burt RK, Traynor AE, Pope R et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998; 92: 3505-3514.
    • (1998) Blood , vol.92 , pp. 3505-3514
    • Burt, R.K.1    Traynor, A.E.2    Pope, R.3
  • 25
    • 0036788483 scopus 로고    scopus 로고
    • Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies
    • Branson K, Chopra R, Kottaridis PD et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 4022-4031.
    • (2002) J Clin Oncol , vol.20 , pp. 4022-4031
    • Branson, K.1    Chopra, R.2    Kottaridis, P.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.